<SEC-DOCUMENT>0001439222-26-000071.txt : 20260429
<SEC-HEADER>0001439222-26-000071.hdr.sgml : 20260429
<ACCEPTANCE-DATETIME>20260429063205
ACCESSION NUMBER:		0001439222-26-000071
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260429
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260429
DATE AS OF CHANGE:		20260429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		26910363

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>agio-20260429.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce38a-6f88-71ab-ae00-739548d11245,g:f4eaefda-ef0b-4492-8a76-1327bbcda641,d:add0a33fdefb4aeb9455638e5b0475d8-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20260429</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agio-20260429.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-29</xbrli:startDate><xbrli:endDate>2026-04-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iadd0a33fdefb4aeb9455638e5b0475d8_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:9.9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 29, 2026</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:17pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Agios Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Exact Name of Registrant as Specified in Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36014</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">88 Sidney Street,</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge,</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02139</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">649-8600</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.288%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.775%"><tr><td style="width:1.0%"/><td style="width:3.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.562%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">AGIO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.439%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      &#9744;</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iadd0a33fdefb4aeb9455638e5b0475d8_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">On April&#160;29, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March&#160;31, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The information in this Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:15.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-42926xfyxex991earning.htm">Press release issued </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-42926xfyxex991earning.htm">April 29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="agio-42926xfyxex991earning.htm">, 2026</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iadd0a33fdefb4aeb9455638e5b0475d8_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">SIGNATURES</span></div><div style="margin-top:9.9pt;text-indent:23.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:  April&#160;29, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:    </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian Goff</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</span></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>agio-42926xfyxex991earning.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i600366839bb148c1a833ba68275613c7_87"></div><div style="min-height:92.88pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Agios Reports First Quarter 2026 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Mitapivat (PYRUKYND&#174; and AQVESME&#8482;) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Strong initial U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written as of March 31, 2026</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pipeline advancing to multiple value-driving inflection points in 2026, including two Phase 2 readouts for next-generation PK activator tebapivat</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$1.0 billion in cash, cash equivalents, and marketable securities as of March 31, 2026</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAMBRIDGE, Mass.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Apr. 29, 2026 &#8211; Agios Pharmaceuticals, Inc. (Nasdaq&#58; AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the first quarter ended&#160;March 31, 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Our first</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">quarter performance reflects strong execution and significant progress against our 2026 strategic objectives,&#8221; said Brian Goff, Chief Executive Officer, Agios. &#8220;The solid early momentum of our U.S. commercial launch of AQVESME in thalassemia highlights both the medicine&#8217;s clinical value and strong community reception. Additionally, following collaborative engagement with the FDA, we now plan to submit our mitapivat sNDA for sickle cell disease under the U.S. accelerated approval pathway in the second quarter. 2026 marks an important growth inflection point for Agios as we continue to build a sustainable rare disease company that is rooted in hematology and focused on delivering differentiated medicines that create meaningful long</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">term value for patients and shareholders.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">First Quarter 2026 and Recent Corporate Highlights</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Mitapivat (PYRUKYND&#174; and AQVESME&#8482;) Commercial Performance and Update</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">$18.8 million in U.S. net revenue </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$1.9 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">in ex</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. net revenue</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the first quarter of 2026.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">U.S. net revenue was driven by the U.S. commercial launch of AQVESME&#8482; (mitapivat) in thalassemia in late January 2026.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">Ex-U.S. net revenue reflected demand for PYRUKYND&#174; (mitapivat) in thalassemia in Saudi Arabia.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">242 AQVESME mitapivat prescriptions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for thalassemia were written by Risk Evaluation and Mitigation Strategy (REMS)-certified U.S. physicians as of March 31, 2026, driven by motivated prescribers and highly engaged patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">R&#38;D Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Mitapivat</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.8pt">Thalassemia &#8211;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">In March 2026, the Emirates Drug Establishment of the&#160;United Arab Emirates&#160;(UAE) approved PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. With this approval, PYRUKYND becomes the only medicine approved in the&#160;UAE&#160;for this broad patient population.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, and the UAE. A marketing application for mitapivat in thalassemia is currently under review by the European Commission.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.8pt">Sickle Cell Disease &#8211; </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">Agios confirmed plans to pursue U.S. accelerated approval for mitapivat in sickle cell disease, following completion of its pre-supplemental New Drug Application (sNDA) meeting with the U.S. Food and Drug Administration (FDA). </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">The FDA&#8217;s accelerated approval pathway expedites the availability of medicines that can fill a medical need for a serious condition, with the requirement of a confirmatory clinical trial to convert to a traditional approval.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">The company now plans to submit an sNDA for mitapivat in sickle cell disease in the second quarter of 2026. </font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Tebapivat </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.8pt">Lower-Risk Myelodysplastic Syndromes (LR-MDS) &#8211; </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">Agios expects to report topline results from its Phase 2b trial in the first half of 2026.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based on findings from the Phase 2a trial, the Phase 2b open-label trial is evaluating three higher daily dose levels of tebapivat (10 mg, 15 mg, and 20 mg) over a 24-week period. The primary endpoint is the proportion of participants achieving transfusion independence, defined as being transfusion-free for at least 8 consecutive weeks during the 24-week period. </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.8pt">Sickle Cell Disease &#8211; </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.51pt">Agios expects to report topline results from its Phase 2 trial in the second half of 2026. This double-blind, randomized, placebo-controlled trial is evaluating three daily dose levels of tebapivat (2.5 mg, 5 mg, and 7.5 mg) versus matched placebo over a 12-week period. The primary endpoint is hemoglobin response, defined as a &#8805;1.0 g&#47;dL increase in average </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hemoglobin concentration from Week 10 through Week 12 compared with baseline.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">First Quarter 2026 Financial Results </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Net product revenue from U.S. sales </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of mitapivat (PYRUKYND and AQVESME) for the first quarter of 2026 was $18.8 million, compared to $8.7 million for the first quarter of 2025.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Net product revenue from ex-U.S. sales</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of mitapivat (PYRUKYND) for the first quarter of 2026 was $1.9 million.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cost of sales</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the first quarter of 2026 was $1.3 million.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Research and Development (R&#38;D) Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $81.1 million for the first quarter of 2026, compared to $72.7 million for the first quarter of 2025, due to workforce-related expenses supporting pipeline advancement efforts, as well as increased mitapivat process development expenses. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.85pt">Selling, General and Administrative (SG&#38;A) Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $48.3 million for the first quarter of 2026, compared to $41.5 million for the first quarter of 2025, due to an increase in activities to support the U.S. commercial launch of AQVESME in thalassemia, as well as an</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">increase in stock compensation expense. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cash, cash equivalents and marketable securities</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were $1.0 billion as of March 31, 2026, compared to $1.2 billion as of December 31, 2025. Agios expects that its cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute the U.S. commercial launch of AQVESME in thalassemia, prepare for the potential U.S. commercial launch of mitapivat in sickle cell disease, advance the company&#8217;s existing clinical programs, and opportunistically expand its pipeline through both internally- and externally-discovered assets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">First Quarter 2026 Conference Call Information </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agios will host a conference call and live webcast today at 8&#58;00 a.m. ET to discuss the company&#8217;s first quarter 2026 financial results and recent business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the &#8220;Events &#38; Presentations&#8221; tab. A replay of the webcast will be available on the company&#8217;s website approximately two hours after the event. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Agios&#58; Fueled by Connections to Transform Rare Diseases&#8482; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities &#8211; collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit&#160;www.agios.com and follow us on LinkedIn and X.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Available Information about Agios </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios&#8217; upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company&#8217;s website under the &#8220;Events &#38; Presentations&#8221; tab. In addition, you may sign up to automatically receive email alerts about Agios&#8217; upcoming events and presentations (&#8220;Calendar Alerts&#8221;) by visiting the &#8220;Email Alerts&#8221; option under the &#8220;IR Resources&#8221; tab of the Investors section of the company&#8217;s website and submitting your email address. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND&#174; (mitapivat), AQVESME&#8482; (mitapivat), tebapivat, AG-236 and AG-181&#59; Agios&#8217; plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including mitapivat, tebapivat, AG-236 and AG-181&#59; Agios&#8217; expectations for the review of marketing applications for mitapivat by regulatory agencies, including the FDA and European Commission&#59; Agios&#8217; strategic vision and goals&#59; and the potential benefits of Agios&#8217; strategic plans and focus. The words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;hope,&#8221; &#8220;milestone,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;strategy,&#8221; &#8220;will,&#8221; &#8220;vision,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios&#8217; current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios&#8217; product candidates will successfully continue. There can be no guarantee that any positive developments in Agios&#8217; business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation&#58; risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios&#8217; business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products&#59; Agios&#8217; results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">future studies&#59; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies&#59; Agios&#8217; ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials&#59; unplanned cash requirements and expenditures&#59; competitive factors&#59; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing&#59; Agios&#8217; ability to establish and maintain key collaborations&#59; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments&#59; uncertainty of the results and effectiveness of the use of Agios&#8217; cash and cash equivalents&#59; and general economic and market conditions. These and other risks are described in greater detail under the caption &#34;Risk Factors&#34; included in Agios&#8217; public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i600366839bb148c1a833ba68275613c7_1"></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.290%"><tr><td style="width:1.0%"></td><td style="width:49.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(in thousands)</font></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045,492&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164,438&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,577&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,920&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184,990&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109,115&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,114&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.284%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,746&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,746&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,726&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,304&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,527&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,771&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,355&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,025)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,629)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,795&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,087&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,111)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,289)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.69)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,782,241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,459,195&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:91.44pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Contacts&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Morgan Sanford, Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Agios Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">morgan.sanford&#64;agios.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Media Contact</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Eamonn Nolan, Senior Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Agios Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">eamonn.nolan&#64;agios.com</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>agio-20260429.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce38a-6f88-71ab-ae00-739548d11245,g:f4eaefda-ef0b-4492-8a76-1327bbcda641-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20260429" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20260429">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20260429_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20260429_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://agios.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>agio-20260429_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce38a-6f88-71ab-ae00-739548d11245,g:f4eaefda-ef0b-4492-8a76-1327bbcda641-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019ce38a-6f88-7381-8570-2020c713e8f9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019ce38a-6f88-79af-984f-56cb402e20b9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019ce38a-6f88-705e-a3c1-a7727f6a5c97_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019ce38a-6f88-716b-95f8-4474bc2d5d1c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019ce38a-6f88-7f96-9b13-314ab166f9bc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019ce38a-6f88-7297-ae77-70532b250880_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019ce38a-6f88-7854-89bc-d14de3ada9c2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019ce38a-6f88-7623-bcd3-2a2aa7515d34_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019ce38a-6f88-7c3e-9e93-b98d3c0851e8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019ce38a-6f88-7d0b-8071-81e0527c06b6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019ce38a-6f88-7438-bc75-bbbf0602aca4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019ce38a-6f88-7d70-b7fb-2fcf7893f771_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019ce38a-6f88-7dfc-91a8-5246fd8061b4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019ce38a-6f88-7a66-91b6-fa194fd72127_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019ce38a-6f88-7a87-87cd-4ef0a4e03c3d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019ce38a-6f88-791c-8791-8349a5f5d2e5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019ce38a-6f88-75c0-a7fc-0027f3850e22_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019ce38a-6f88-7b67-bad8-e4d0eee8d9bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019ce38a-6f88-7f7c-a853-a06c09e21fbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019ce38a-6f88-78f0-a7bd-dc44b8452e61_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019ce38a-6f88-72c4-86cf-a5d5ff13122c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019ce38a-6f88-7324-a2c5-f64a1f6e0d6a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>agio-20260429_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce38a-6f88-71ab-ae00-739548d11245,g:f4eaefda-ef0b-4492-8a76-1327bbcda641-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="agio-20260429.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://agios.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ce38a-6f88-7612-b2d2-ed4546eecd7a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_AmendmentFlag_019ce38a-6f88-7612-b2d2-ed4546eecd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ce38a-6f88-738c-8977-54dbe217f2d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityCentralIndexKey_019ce38a-6f88-738c-8977-54dbe217f2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ce38a-6f88-7820-8483-aab07f84a4ee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_DocumentType_019ce38a-6f88-7820-8483-aab07f84a4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ce38a-6f88-70e5-89b9-3a8a5108a3db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_DocumentPeriodEndDate_019ce38a-6f88-70e5-89b9-3a8a5108a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ce38a-6f88-71b2-a8aa-0c900457c7bf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityRegistrantName_019ce38a-6f88-71b2-a8aa-0c900457c7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019ce38a-6f88-7287-b674-ef1ef07d69d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019ce38a-6f88-7287-b674-ef1ef07d69d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019ce38a-6f88-7122-b628-4067921e23f4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityFileNumber_019ce38a-6f88-7122-b628-4067921e23f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019ce38a-6f88-77d9-9fa0-19894f38004f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityTaxIdentificationNumber_019ce38a-6f88-77d9-9fa0-19894f38004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019ce38a-6f88-7fcd-a19f-9845c17fcf30" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityAddressAddressLine1_019ce38a-6f88-7fcd-a19f-9845c17fcf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019ce38a-6f88-7a10-b063-ea4180a68bb4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityAddressCityOrTown_019ce38a-6f88-7a10-b063-ea4180a68bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019ce38a-6f88-7b80-ab5f-8d8d9a7db959" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityAddressStateOrProvince_019ce38a-6f88-7b80-ab5f-8d8d9a7db959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019ce38a-6f88-7782-b0b4-d734d11781e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityAddressPostalZipCode_019ce38a-6f88-7782-b0b4-d734d11781e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019ce38a-6f88-7bd3-965f-1d9a20adb9e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_CityAreaCode_019ce38a-6f88-7bd3-965f-1d9a20adb9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019ce38a-6f88-7420-977e-5b19a6c579df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_LocalPhoneNumber_019ce38a-6f88-7420-977e-5b19a6c579df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019ce38a-6f88-7fd4-b7c4-38c9cc218339" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_WrittenCommunications_019ce38a-6f88-7fd4-b7c4-38c9cc218339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019ce38a-6f88-71c0-a48a-75b3db114a60" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_SolicitingMaterial_019ce38a-6f88-71c0-a48a-75b3db114a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019ce38a-6f88-7256-9b2d-0cddd70b68a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_PreCommencementTenderOffer_019ce38a-6f88-7256-9b2d-0cddd70b68a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019ce38a-6f88-7036-8092-8b904be88b7f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019ce38a-6f88-7036-8092-8b904be88b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019ce38a-6f88-7a26-b2c2-ff87628775e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_Security12bTitle_019ce38a-6f88-7a26-b2c2-ff87628775e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019ce38a-6f88-749c-b01e-bf464e1de3a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_TradingSymbol_019ce38a-6f88-749c-b01e-bf464e1de3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019ce38a-6f88-75ba-8b8c-8ae55a633e50" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_SecurityExchangeName_019ce38a-6f88-75ba-8b8c-8ae55a633e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019ce38a-6f88-768f-ab35-2998c325abb2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce38a-6f88-7621-a810-e42535daf285" xlink:to="loc_dei_EntityEmergingGrowthCompany_019ce38a-6f88-768f-ab35-2998c325abb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  "E$   '8" 8   #7Z%P6     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  ,L   #+  2AD6ML  .0S241!
M5'A>[-T'F!QG??CQ5\5RMVS)TNGN=N=]1Y:ENYD1)::$:DA"24CHHH6$ $&
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M]!9Q,Q@1S:XDW:Z2_'(5;WVM?=0!      # >8-'2)L674N;X!H[8
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M/[+C!P       /K$VBV'J"1[CDKR7>*F*R*J;TE[PW365./C<^TS @
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M?M$"E62GJ"3=+6\N(B+JH^+\']1IVTZPSY        "5I'7X5&EC8I6R4P$
M      "ZY/3L1-7*KA,W$1$145'V'M4Z;[%]U@0      *B,I4M/7"YM3*Q*
MVH3WV*D         '9;D[U9)NE?>,$1$1/O5?LY,LK^TSZ(       "5(&U.
MK$K:C\ZWTP         Z8./$D$KRR\7-041$-)U^6?1J^^P*      #@+&ES
M8E72>M53[30       " 66BE;U%)=OL#-@ 1$5$GBM/OJ];6/[#/N
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M_CUQ@PX1$;E?G-^EDNS=]AD=      "@ZYK-\ 1IPZ)K:1W>:H<,
M/, ;SENLQO)+]]N,0T1$U2W)+E6M\QYGG^D!      "ZQICH"]+&19<Z[KCE
M"^UP 0       "M.3U9)=K6X^8:(B.I1DNU2R<19]ID?      "@*SP=[90V
M+[J0]J-WV6$"        A23]?97DMXN;;8B(J+[%V<_4INQI]K,!      !
MQWC>2E_:P-CKC!]^RPX1        ?2^>>.KD*Y))&VN(B*B_:J5_KUH?.LY^
MA@       )@USPL?+VUD[%7:A+^R0P,      $!?V[CMJ>(&&B(BHCC=J<;S
M9?8S!@      P*P,ZU5/-7ZT5]K46&;&#[?;(0$      *!O;=KZ_,G-,=*F
M&2(BHOO7_GS12O_.?@8!      "8L46+5C2DC8UEY9GP]F(8<Z9& P
M@/ZS*7VU2M+MXB89(B*BARK)OJ/B=(G]K (      #!M@X,KC_=,L$O:Y-C-
M/"_<9H<       " OI.D:U6<WR-NB"$B(IIN27Z[BM,WV,\R        TZ9U
M<(&TV;'3:1/<XWGA$^P_"P      @+X23SQ7)?D.<0,,$?6^.+]JYO&6_.1(
M27JNVCAQM/W, P      <-"&ADYH:A-=)FU^[$3:C]YI_RD       #TE63K
M8U22[1(WNQ#10Q?G-ZFQ])JB'Q=]I?BU3ZM6]A_%X^IO59QN4''VLN*_'ZTV
M9:OMHZY:-IT;3HZ]/8]VD_/*_V%RCG'^ORI)+[%SOU$E.<\E='"UTI]6]C$!
M      !Z:LF28)G6T=>EC9#3K?U6X69Y^&[[H0$      -!7-KY_2+4F[A8W
MMQ#U:W%ZMTK2FU627ZN2['(5Y_^HXNQ-:M.6QZN3Q^?;1P^F:_V%AZM-Y_[V
MY+%L']/VL9T\QL6Q'DNWB^>"^J?6Q-.5^O4<NUH        .FC&C+S)^>(TV
MX2YIDZ247A[>ZOFCGU9JX$C[80       -!7UI]Q.&_M2WU=J_WJB?E?J]:V
MD]3X^(*IS9%LX.J]XARLN6B>6KOE$'5:ODPE$Z]3\;:+59+N%L\CU:LDW:M:
MV85V,0       ,S$/*6"!<WFB4_2.GRS[T=_W:[ICSQ-*7U8\?OM'Y+F^X
M      !]K95^6]R\0E27XNS[ZO3T?2H^]TFJM76%.G7+\6K-FGGV$8 Z..6L
MHR8W66[:.EJ<\S\NSGFFDO2*_=8"5;<X^Z%:<]$">\8!              "
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MDF\4-X<0S;CT&K4Y_Q>U,3O1KC( KFJ_ G&2?KCH2OGQ3 =5DKYO\@<2
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M'40/K+U6XNSY=O4 P,R<GC]7)>G'U%BZ6WRNZ>?B_ MJW9E+[)$"
M      ! U[2R%XL;.(CN+<EN56/IA]7&=QYM5PT =%YKVRN+YYMOJ3B_1WPN
MZL^^J4[+E]DC!               @(YY_=G'"9LUB*:*\YM4DK_9KA8 *-N<
MXCGH+2K.;E!)NE=\GNJGXOQ[:L/Y1]IC P              @%E)L@O%31K4
MW\7Y':J5/5JMN6B>72D X(!?SU&MLX]3K?S3XG-7O]3>3!JG/[4'!0
M         -,63T0J2;>+FS.H/VN_NEF2/X*-DP JXTWYL>JT_)G%\]<-XO-:
M/Y3D7U?CX_/M$0$              ,!#2O+_%#=B4#_V:=6:>)Q=&0!0;9LG
M'JGBB:W"<UW]B[./V*,                 49R]3-QX0?U5G'U.C6U[LET5
M %!/Z\X\5,7I!M7*?RX^%]:U)+O '@$               !,:IU]G(KSGXB;
M+:@_2O*OJLW9[]@5 0#])\Z>IEH3_ZN2=*_X/%FWXOP,M7;+(7;V
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MT\7'%=6C./N9BB>>:L\V ,!%K?0/59)=)CZ/5ZTX^YP:/^LH.S,
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M3;XJ(-!MXQ?/5TE^F;@6J1K%^9[B?S]MSR@   >O_0KI5?IAK=;6%]N1 P
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MVM,& ([8G#Y1O-%&1$79:6KSEH7VT8)>&A^?KY+\O^7S1#TOSFY0K72Y/5L
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MKY+\$RK>.F ?_?6Q=LL1*L[N$.=,Y93D7U=KUQYBSP@  *B;>-MZE:3;Q>N
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MVYS]D8JW75P<ZSM5G-VSWWD@ZG8;)YYM5^/^6EM/$O\.=;;V8S\Y[U'VJ ,
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M/=)Y=#$[9*#FXNRGXHV4@RW.GF\_$H!N:;_57BO+Q<<@4<?++BA6'3?2 0
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M1/\HG5/7&AH:X5TM43.MB:O$&R0/5KSM"_9O JB")/M7\;%,],"2[(MVU0
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MZ'>MLX]3K?0K^SU74+5+LG?:,PP   !,3_L=*Z1KS/N79+=/OH(E -2<=-/
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MSAW)^.%N.U3 (7$^LL\-BB3]F/T= "C'^ 7'J"2[>I_G(JI.<?8F>R8!  "
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MRR9*XP<?E>;G:EJ'S[=#!Z;MF$:P2%I7KJ;]\$8[=.=(XW4IXT>?LD,%  !
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MT=^U4P   .A#8]F+'[!)K>2R]]B1N.DM$X]3K>P>>>S4F[+KBC,S9^H$ 0
M +/4.ONXXCKS^LEKS=;$']M?!0"@<MA$V7G&#VZ6QN]B#1T\TPX;Z+KAX1,?
M*ZU#5V,39;E5=1-ET_#VQ<#]&1.DTMIS,:U'_]T.VQ7SI7%6H68S>IJ= P
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M/Z+UZ'/M808  )4V=KZOQK*;Q0U>U/GB?,0>>7>,C\]72?9E<;Q41I?:,P$
M     &K$\TY<[GG1LXR)QLWRZ"-Z>?ACZ>8;E9/+FRB;S=%0&K.+&1.>9H<-
M](PVT772^G0I-E&66Y4V40X/CYXHS<'%/"]8:X<-E&[QXE5'2^O2Q8KK_8_8
M83MK>#A\N#1VZG3A+9X??ESKZ'7-9GB"/?P  ,!IZ\X\5,43'Q<V=%$WBM/;
MU*9S&_;HNVGSN<\1QT[=+TGO5!O.7VK/!       J "M@V6>%S[!\Z*7MU^=
MSYCH^_*--'(AES=1%F-[BC1F%S,F?+$=-M S_O+H,]+Z="DV499;E391-DSX
M#&D.+C;HC9QDAPWTPCQI7;I8\;7 E^V8G:;UZ+])XZ?N9_SH8NV'IWC>R&\5
MIV+^U!D!  "]%^<O$3=R49=*OV*/?!7,44EZA3P/ZGJ;)QYISP,      .@Q
MK?6QGK?2'QY>]51CHG<;$[))LL*YO8ER]+G2F%W,\\+'VV$#/>/[J\>D]>E2
M;*(LMRIMHBRN*<Z6YN!B=LA SQ@_W"VM3=?2.KK2#MEYQ@_NE.9 Y:=->(=G
M1M]AS*I5[:\][2D"  "E:+]M<YSN%#=O4>=+TKUJX\20/?K5$D_\[N3XI7E1
M=XOSECT+      "@N^86S5^V[,11WU_]5]I$ETDWMZ@>N;V)<O6?26-VL:$3
MPJ8=-M SQ>,YD=:G2[&)LMRJM(E2F^ ;TAQ<S X9Z!EM5N^4UJ9K%8_K77;(
M57"H- =RI_;GM.'AE0\KSM6\J5,&   Z:8Y*LLO%#5O4G9+\TLE-JU76?LOW
M)+]6G!]UMSC_GCT+      !@EH;-Z&.-"=^A3?1]XT?7:;/Z#NEF%=4[IS=1
M^N';I#&[F!TRT%--?_1)TOIT*391EENE7HG2C_9(<W Q.V2@9XKK]QW2VG0Q
M.^1*\+R19TES(#<K/L?=:OS5/_*\Z(W%Z9LS=18! ,#T;<[>*6[2HNX59\^W
M1[\>QO(_V6^.U/V2]!=JS44+[%D        'X)TP\EN>"=]A3/0EXT?72C>?
MJ+]S>1.E[Z^^2!JSB]DA SW%)LIRL(FR.Z3QNYH=,M SQ@^W2VO3Q>R0*T/K
MX)W2/*@:%8^-.XT)+M%^]*YE7A#8TPH  $2MB:>K)-LN;LZB[M3*KE.GG'64
M/0/ULG'BZ,GY2?.F[I6DN]7I$ZOL60      H.\U&L$*8\(WZ>71OQL_N$6Z
MH40DQ2;*SF2'#/04FRC+P2;*[I#&[V+&#^^R0P9ZQE\>?49:GRYFAUPIQD3?
MDN9"U4WKX+O&!!_0>O3W[6D& *"/;3A_J8KSJ\0-6=2]6OG;[1FHM_8\I?E3
M=XO3%]HS      ! WV@T3ASV_.CEQH\^)=T@(II.+F^B+-;X#Z0QNY@=,M!S
MTOIT*391EAN;*#N?,=$/[)"!GO']U6/2^G0Q.^3*\71TE30?JD_M'SXT)LR*
MS^LO;#2"1?;4 P!08^,7+5!Q]CEQ Q9UKSB[2:T_XW![%OI#>[YQ>HMX/*A[
M)=F[[1D      *"6VAM.FNU7F?1'[Y1N_A#-)C91=B8[9*#GI/7I4FRB+#<V
M478^K5=_U@X9Z)DJO/+PO=DA5Y+QPRND.5%]*[[^V&N6!^/%UTBCQ1*8/[42
M  "HOCDJR<?$35?4W>+T#'L.^M-8]A'QN%#W2O++BR,_9^H$      !0;8.#
M@T<T=?0ZXX>[I1L[1)W,Z;?S%L;K:G;(0,])Z].EV$19;FRB['S&#SY@APST
ME+0^7:RY/'J4'7(E:1-<+<V+^B?/!!\^;OGRA<5RF#NU*@  J)(X>[Y*LEWB
M9BOJ;NO.7&+/0G_;,*'%XT/=*TFWVZ,/     $#E''^\-^CIX+O:A+ND&S=$
MW8I-E)W)#AGH.6E]NA2;*,NM*ILHCSIJ\'AI_"YF3+C)#AOH*6E]NEA#AR^Q
M0ZXLXT?727.C_DN;Z#;/!&^U2P,  (=MG!A2<7:#N,&*NEN2311G@%<"O+_Q
M\;G%>ORA>+RH.\7I3I6<,VC/        3O.\D3\T?O1#Z>8,45FQB;(SV2$#
M/2>M3Y=B$V6Y5643Y;)E*Y9(XW<Q8\+3[+"!GI+6IY/YX>OMD"O-\Z//B/.C
MOLWXX5W:A)]?O'C5T7:9  #@@.2"095DEXJ;JJB[Q?E=*DX#>R8@:>5KQ&-'
MW2O)7V"//@      3M$Z?+[6T=>EFS!$O8A-E)W)#AGH.6E]NA2;*,NM*ILH
M/2\(I/&[F#'AB^VP@9Z2UJ>+>5YXCAURY35U\$YICD3MM!]<Z'DK?;M<   H
MV?JMBU22?DG<1$5EE-HS@8>R=LLAQ5J]0CB&U*U:V=_:HP\     0$^U-P88
M$WU*NM%"U.O81-F9[)"!GI/6ITNQB;+<V$39^;0>?:X=-M!3TOIT,6-69W;(
MM>#[X1\9/]HCS96HG?&#W4T=_F6Q7!9,K1H  +KI%?EA*LDN%#=.4?=+TCO5
MV(2V9P/3T<K^7CRFU)V2[,O%4>=MY@$     O;! Z]%723=5B%R*392=R0X9
MZ#EI?;H4FRC+K2J;*(V)3I;&[V*>%S[>#AOH*6E]NICGAU^U0ZX1?5CQ_'JK
M-%^B^Z=-=(/GK>+S!@"@"]JOYA?G6\7-4E1.K?S3]FQ@IEY_]G$J3G>*QY<Z
M7Y)NGWSN      "@!%KK8YLF_+9T X7(Q=A$V9GLD(&>D]:G2[&)LMS81-GY
MV$0)5TCKT\6T";]GAUP[6@>?E>9,)&5,L+E8-MRS!@!TP%A^D4K2O?MMD*+R
M6G?FH?9LH!.2[#+Q.%/G2]+=:OT9A]LC#P    ! %PP<:?Q@NW2SA,CEV$39
MF>R0@9Z3UJ=+L8FRW-A$V?F&3@B;=MA 3TGKT\7JO(FR;6!@-)3F321E_&AO
MTT3?LLL' (!I&LL^HN)\C[@QBLJIE>7V;*#3QL[[/?&84^=K;Z0\?>NH/?(
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M/>G8$#U8Q>/FVL6+5QUMUQ  H/:2_#_%34W4BVZW9P4N&<M;#SA/U*T
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MU]G3"0"8M5>]\VB59+\4-PU1[XOS/9,W=H"#L7%B2%Q'-/N2=*_:M"VT1QH
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M2OL[ %">L7R-BM/;[GL^H@J5)<499!,^JFU\?+Y*TCOE-4XS+L[_QQYA
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M=C66OM3^+0!UE:1O+KI"?!Z@:I9D%TZ^FBB  TO.&2P>+SO$QQ'-K/;S#P
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M?E0 L[%Q8I5*LK-4DFX7'FM4QY+L,G5Z=J)= 0!Z(<F^*#X^:68EV=GVR (
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MD;)#Q4$;3S>H*+YMKR=7B6AA"I-_5-'6$^PM% !P(%'R5/%Z2K,O2IYC5QD
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M/>(3L$0T!\6WJ3#]H!K;LM+>\@  LQ4E#YY\IQWQNDNS*HRO48^?.,2N-
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MVA(5J>R^X%Q[RF(&>K1>*ZTKS4W98^*;]>#HM?O,!'=+?X^F5U.WWFA/90
M *"$QE(COIA.\U\[^:D:VS(OOQ$'  !*KKUCC0K3R\7'$'-5F-ZJPKC'?D<
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M&ILHT6V.&VPWKK]+.L:T\!DWN,0>*F#&M!N$V>W\=ND<HV*77Y^U&7F?/90
M    "B>,;Q8W"E QBN(]*MK&QTX! .HG2J\5[QL7HBC]+SLJ )B5E2OUT=*+
M*30_]?>/K+=+7RK]9GA8FD\1RS]&U X;0,%)M^&BIK7W COL4F,3)19*P_4>
M+AUG6IBTZYV:'1;>+ %S3*]P!KV;I'..BE=#>T^S!PX   ! H8VG_['79@$J
M5F%\G3KEPJ/L$0, H+JB^-OB?>%"U=[V$#LR )@S:]<.]>2;SZ075VAV:>UM
M6S4XN-(N=6E)<RMJ=L@ "DZZ_18UQVT]Q0Z[U-A$B876VSMX;/;8Z$+IF-/\
M9DSK)XZSWK6' IA/BYM-[_>T"6Z1SD5:N(P)OM!L#O?;XP0   "@-*)XJ[AQ
M@(I5E'S&'C$  *KCE,W+L_NX?Q?O^Q:J=N?GZJ7I"CM" )@O2QJ._RKI!1>:
M?MH$7W6<D4IM>I?F6=36K.&%0:#H!O3((Z7;;U%K-$9'[=!+C4V4*)*&"1ZO
MM?\]Z?C3W&1<[P:M1_Y?MMQ+IU8=Z+JE#3W\PNSGH^NE<Y3F/^,&_]LP_E/M
M\0    !06NWDM>(F BI>8?Q&>]0  "BOL2TKL\<?GQ3OZQ:R,(GL" &@:]:N
M-=J8X!^-&^R67HRA!V9<_Y/-YLCOV^6K'&W\]V5SO+(,:>W_I1TV@(+2.GBU
M="TM:BM7ZJ/MT$O-,=X'I.MF$=.N]R$[;-2 XWH;LL><ETBW/SJXLL=!US?U
MY,=U X6CM?="8[RO2^<NS5W9-?7R[#[_)+OL     "JCW?D#%<5[Q T%5*S"
M9*<*MS_1'CD  ,JC_?Y5V7W9I_>Z;UOHPO1VM6EKPXX2 !;,P,#ZXQW7_Q=M
MO)W2BS1U3)O@YJ;QW]]H>$-VF0  TV2,GTC7UJ)FAPV@"YS!UI/S=TTUKK]+
MNCW2WFGM7VI,ZZ_L$@*ET-L[;!PSDCC:NU8ZKVGZY;_XF%TS_[.A@^?9Y04
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MTR0 S#/I6ES4C!M<8H<-H&!6#0ZNS-^]SAC_'Z7;;VES_?]RG-:3\\?5=JH
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MO>/9M?D>\9I=ML+.!Y7ZOT5V;@    #V0VOO>])FQ:)F7/]B.W0
MJ+@H_K:X,8*J593^2HUU'F>/.@"@F\(M(RI,/R=>G\M8F-RN-G:&[>P
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MICIIRU([:P  @'G1KX=.E#9N%37C!E^R0P<.BN/ZKY+.J2)G3/ %.WP
M    P*27IBM4%-\F;K2@>A7%OU;MSJ/LF0$ U3?>T=FU[_/B-;%JA>E.=49Z
M@ITY  # ?%LA;=XJ:MIX.^VX@8/B:.\FZ9PJ<@TS\G@[?         #  T3Q
M=\5-%U3/VO$EZO0+#K=G!P!4QRF;EZLPKO['==^_L>3?[>P!  "Z1MJ\5>2.
M.JJQV@X=F):^9NNQTKE4].SP 0        "B=N?5XN8+JF]1?(<*T[/L&0(
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M,+U>O)V37)A<9E<0  "@,HSK[Y(V>16]@8'UQ]LIH'X6:>/OE,Z+LF3G 0
M      #HFK#S7'$S"-%LRM^-+4H_;L\R (4WL3B[W7YJ\K8KW:9I_[%Y'
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M=,S+EC'!*79*         (!"&4\WJ##=O==F$J)N%<7?5>WX*>J4"X^R9R6
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MB,I6E'Y$C7?^0(WM<.S9#1S8*9N7JS.3=2J,_R0[?_Y%/+>H>(7)%GL$ 0
M, /&#79+&\/*F..V/FVGA>(YQ'&#[TC'K>SU]7D\]P          E;)A8IF*
MXMO$C2I$92]*SU*G=[0Z^=PCLK-]T=1)C]K)-TOF[\ [ECY?A<E7Q'.%BET4
M[U%C\27VB (  & 6C&E5ZIT!M?'N6;-F^$@[/13 VN;P0Z5C584<X[W-3A,
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M('M6    8)XTF]Y+I8UB5<BX_L4]/3U'V*EB'FGM_V75-T_F-9NMQ]HI P
M      !J8V+B$-5.OB%N<"$BN2C>H\+X)RI*/I/][_>H\>2T['__B6IW'J5.
M>T]3;=BPQ-["JF_#Q#*U:6MC<N[CZ89L'4[-UN?=V77EWU287/: =2.:++E!
MC<=/L6<0    ND ;_SIIPUA5,B;X<#;-95.SQ5S2NO4*:<VKF.,&G[;3!@
M      #44I@^1D7I/?*&%R*:L\+TTNRV]@D5)N]343*FPGB3BN*G3]:.'S'9
M6/P@M3%9-]GI%QRK3MVV^KXFTJ/MK7;Z[O_W\^[]VGGW?L\P>>SD&,Y,GSLY
MKO'DS9-C;,?_.3EF:2Y$!U,8WZS&.L^W9R4   "Z:Y%Q_5W2QK$J94SPU69S
MN-_.&;.@=?!J:8VKFJ.]7]FI P        !J+_\88VGS"Q$1T4R*DKM4V'FB
MO9<!  #  ADPZQXD;1ZK8H[V;QH86'^\G3JFJ;]_9(TQK2]*:UKE\@W&=@D
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MH>5VF0]:_O=7#0ZNS+_6Y-?-O[[KO]*8X#Q'CUXEC8>FEW&#']AE!@
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M$5%WB^)=*MH^8:_0    P%[6KAWRC!OLD3:H$16U[)S=W=]_7-.>Q@
M    %-#&],GBAAXB(NI.&SM/ME=D    8+]6KQXZ2MJH1E34M-8K[.D+
M     $#!C<>O%#?W$!'1W!?%-ZBP$]@K,    #!M?7U]AQDW^(VT88VH*!D3
M?"T[71=/G;4          )1).WV]N.&'B(AF7SO]F#IMRS'VB@L   #,F';]
M?Y4VKQ$M=%H'K[:G*0          )3:6O%W< $1$1 =7F.Q487R6O;H"
M<T;KUBND36Q$"Y$VP:W''NOVVM,3         ("*"-/WJ"C>)6X,(B*B?1?&
MUV5_;K!74P   &"^+#*N=YNTJ8VH6S6-_TE[/@(         4%%A? Z;*8F(
M#E 4[U'MY*?957/1U,43    Z [''>'CO:GK:>/?TV@,C]K3$         "
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MA[@!B8BH;$7Q'M5./JDFTA7V*@<   "4DC%^(FV.(]I?V7ESY=JU0[P+/P
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M*VYP(B*:ZZ+X ZH=#]HK$    (#?X3C!GQG7NU':<$?5R3'^._/-L_:P P
M      " 0HB2<U64WB5N?"(BFFE1_&T5ID^V5QH     T[!V[5"/X:.^*Y76
M_H^:KO\L>X@!         $!AA=N/5V'R,W$S%!'1=(KB:U08O])>50    #,
M0D.WGFM<_TII8QX5.VV"6[3VM]A#"0          2F<L^:(*T]WB)BDBHOL7
MQG=G?[[!7CT     S /'\5]EW.!.:<,>%2-M_)U:MSZ6':XE4T<-
M  "4W2(5;7OX7ANFB(CRVO&[U,2%1]GK!0   ("N\)8YCO<DX_J[I(U\U/VT
M]M_=:'BK[0$"          "5%,8]*DK>(6ZD(J+Z%"9;5'3^@+TR     %A@
M6GLG:!WLD#;WT?RDC7]=T[2>LW*E/MH>!@          4"MAYXDJC+\O;K B
MHNH5)>>I]K8A>P4     4%R'Z$'_C[0;_*NT^8]F5KYI4KO^FQN-X5&[S@
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M^_O^_I'U=KH           !=,)XT593<)&[@(J+NUTY^J=K;AM2&BY;86RD
M    [,\BI8:6]_1X1PP,##6T]EZ@M;^U:!\/;HS_>6."M_;W>R>L63-\I-9Z
M13;VQ5-3            6&@3$XM5>\O#5)3^0-S8143S5Y2<I\8O<.VM$0
M  #FU>JAH:,:#6_UP,!H8W#0<QS'R_YC*JU''WF@[O_O]_?[S?SK:*V/SK^N
M_18            E%Z9/SOJ"N.&+B&99\ETU%K](G7[!X?86!P
M       HI&C;PU64_).\&8R(#EB8W)K=ALY5F[;[]E8%
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M86*9"M,1-98\2T7IA9,;[Z0->53<PLX75'O[:U6[\RBUL=-OCRP
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MWX@Y59C>/H-N?<#7&+_O:V=EWR]O/&YG_VR3&M_VA.S??XP='0
:  I#J?\/YJ?I;ARU2JP     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 29, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 29,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Agios Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="agio-20260429.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="agio-20260429.htm">agio-20260429.htm</File>
    <File>agio-20260429.xsd</File>
    <File>agio-20260429_lab.xml</File>
    <File>agio-20260429_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "agio-20260429.htm": {
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20260429",
   "dts": {
    "inline": {
     "local": [
      "agio-20260429.htm"
     ]
    },
    "schema": {
     "local": [
      "agio-20260429.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20260429_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20260429_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://agios.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20260429.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20260429.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://agios.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001439222-26-000071-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-26-000071-xbrl.zip
M4$L#!!0    (  (TG5S]I'$O51    !^   1    86=I;RTR,#(V,#0R.2YH
M=&WM75MSV[B2?I]?@=7LGCA5)L6;+J1MG=(H3D9G$MME.3M3^[(%DI"%#45J
M0-*6]M>?;I#4Q9(L*I$MV;$?$I$$@4;WAT9WHP&>_G,\#,@=$S&/PK-WNJJ]
M(RST(I^'MV?OVKU.M_ONGZU?3O]#4?[Z[?HS^1!YZ9"%">D(1A/FDWN>#$@R
M8.3/2'SC=Y1<!33I1V*H*-EKG6@T$?QVD!!#,^I%L>*I<#3=]IC9I$J]WVPJ
M#9VZ"F6:IC1,NV8U?5TWK-KQK=.W&&5]GRJLK[F*9=F&TJ2-NJ*;1L-U/9_6
M+?W8=ZCO:]0T^S[KNQ9EKFW5:G6SR6JN9C5J?E.V.TB@S]#O,#ZK#))DY%2K
M]_?WZKVI1N*VJMNV71UCF4I6R.'C1(F9MU 8KM7;Z*[*PX"'#'E3300-8^PZ
M38"954/3:XK65$Q]5L]"%6-7!+)%*&G.5337[.KRC[5I:(IF*+I15#*.^:I.
M&IJF5__Z\KGG#=B0*CR,$QIZK'C+9[.W9+-%=^$!-E*;5@\/^;I>:=BKQ8J!
M\&^/%,?'+HVGQ<=+Y1>$A$]E42>@@-<*"Y6OO4KK=,"HWSH=LH02?%5A?Z?\
M[JS2B<($L*O<3$;0@I==G542-DZJ4M[5UB^__'*:\"1@+7K+(P4AJUF&?5K-
M;IY6LZK=R)^T3GU^1^)D$K"SBL_C44 G3AB%# C@8P<+,I']Y+[/0OD3GE_
M !+<R]H?)]>L?U;Q% !)2(=8$^/.>0C-33I G:!!-_39^ \VJ1#NGU7ZBJ%7
M6AJ(SS)MPS!.JPNU;M%(&\:QCV/Y8T!O*R0#T5D%4.?T^9CY2I\&*(F\5:/2
M^MC^W#M?:K"ZV$/!^DR "F'Q"L&@P)Q88@Y((E* 3@+B.*O$?#@*4/#RWD @
MQ0LR4,>Q#Q*2[<T:R=N,HU3(*PE()^^VI!V[7=QGDK'%%??QNL^9()(FMG*$
M=[I_+#+\X<NMXM9B[2-@3^075S ,1/(!5&8+^Z-HEH*H>OAL2J:_IFCQI+@N
M&JDN]+M@TI0KU3E 5@&V&7:1.WR3QOQ?Y-[LG1SO0QXJ X9JW;%JH^3DGOO)
MP-$U[;\JLESK-!Y1 (0K4&+9[ZR2I:J08(4&_#9T/. @$Y7LY>*Y%P61<'[5
MY-])'WH(R!SR8.*\N^%#@-D%NR?7T9"&[XYC8$<_*Q/S_V>.;@!M\O(^([8!
M5:#R+(C/*/YZT;TY_T!Z-^V;\]XBN8=%:.^\\_6Z>],][Y'VQ0=R_E?G]_;%
MIW/2N?SRI=OK=2\O]D)]LQ3Q?[9[OW<O/MU<7AR3#VI'!8.@9MEK"1Y2<0LH
M<Z,DB89.'9K([R31R+%5&VZLZE-"W8 5=;B1 ,PKT+> CF+F%#]."GV=3:6*
M?.EDL46$-1A&"?=HD#<BV\L>YX@W:JK1;"+H$QA:B5\TG(\'%?I=7;YO-U5;
M6_U(4W5YORKK$\7#G)% 4T6^ QU!MIU5S,J#ON;4ZZ.$Q%' ?8(B/1G!, >3
MSM$(/)C67Y7]+L7[)P6_M0D_!N+GX^7U%U)^?BM,U6RVSV8QT&5-Y8_E*6R+
M,?.SXPM'WT[ ]?@PWAFVM%*Z"=3J]?G%#;D^O[J\OMG/%%".TJM4Q"D%#RR)
M2(]Y:/;_XU>]KIWH)HD$T6M'_GMRH!V0PSCJ2W\1:$\%3SC4>3[V!F F,M+V
M$@*/==NT-DT+!X4>-,F0\&LVBD1"CHIK1L$H8W%"V!WZS$(^9OY[YSO4V)6T
M],XS^V_17/?ACC*$*@;XFN+3B3*!IA463JWW2JL]$CP@AGTL_? W%;A.!>K/
M/,<^$Y ;I8"\K8MZS6YYC#&(Y *>%&@S 6W@N<7D:D !I1Y+I83C8](-/;4T
M]!:Q@G)Y4A:5,V*/SL<4M!1V-QOQ!0,(C4EOQ#QT"7W"0]*!S@.%[]^&UC9#
M:VOS8E?BMQ^(WUHY>653;?;ODF"?6WPVZ(VFM:WX3$MMZ,U'Q5?^OEVWMWIC
M'5&&K=:U;1M_:J),3=4LLPS0UX&Z@*XQ&B-XY_57P/I+(AYRWP_8$^JT)5!K
M,U!/X9SX.^I.!M97TYTWZ1QR=PY'.M^O$S(SX-D%M1M;$&R[2("#(U>B>@GX
M))TH#1,QZ43^HL."BVD8]$[82$1W6,_,4[' FV(!O:>"K344#W<(U-7:LPV"
M%PV6CSQ@4-@%HS<7? T7673%!#/ >I/\ZY7\#1UW\Z4S3ZJ*11C4*RU<\ZK7
M#5NO/8J##6IVSI_0U$9MP:68]RI*\Q=J>GYO4^I1C.M=)@,FR+]2P6.?RZ@?
MNI\+.O?]"Q@F.[817H>0.]%PR&/,P"&H%TDV(M[$^4+%V;WND?/A*(@F,&(7
M=1VYB-3WRUIL*4:X'PF]Z+"&7E<-N[$3O]]6:PUC-V$-M6GMAB:]H=;UQV,1
M9:NRFJK>>#RF\G.&-:8!QIT4>R4Z^<7*^B=UP]N^+U@<Y_]]AOKTPK9N5%K-
M)NEQ/V03TDL$8\GQ0Q.;E)^F<YVNJ;75\?I7RMD._+P4-]']-&;1K+0Z=.@*
M[M^R)8:^\7,#/Z6+<RFN1'3'9:9PQE2[TOK2?@L$O'I%=17%"0W^AX^R,&&>
MIZ556IJAF_;V$0![M3?QHV-J+YY$SB+T]*\$# X^H@$Y'S,O3?@=(Y=]\"M8
M_.8HOE!'$4!/$/6'ZQ&6R<)Z\NS0<CE8LTR,?_S:-/3&24P2%K#1( H9"65$
MY9C & I21 :A@E% EL\<<E1><^'<WX8W%W257FG5]<9#3?5^BQROSQ$@\0HI
M70R&Z@94;=E*LZYIZPVULCE^J[+Q5XO4W'>JC<RU./H8">AKGFLC2'Z9*T40
M9A]S;,);YH--"Y8#^4SC),_!^YFS;LJ:F8>G-Y=V06SG[)5.M7M*[;2:Y,Z
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M1TX[ P,T3D'C4E"^F,H-BH]14/<T#$$_>S+)*\';&<M0S:/^_3N5AX>1;#H
M/\@;9(V:>M:H9&<D+5XWC8%2J'L I 9(;JR2-H!G-$WT6FP;K,I^*D(>#Y P
M-$@'W.4) 2]&QQE!VIV=5 A<1,C/-,2]R7ERFEHFA107@/80K8.^\G!Z'CX:
M];(S!>GS&<#SO3[&*$L0R/G89> 3P#3O$TPD-H!2'C!?_M9/I(!@]H19B4F
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M2@L-L:?2U8\%C/K]YY;G*5WIYK,,W2?[I(W,?7G',FRC/NY/QFQLVSJCX#*
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MBY[<0TX0<U+G77T^;U?6N[3>Z*;?O\[@\'EN[WM/V!JV>V$^^ -02P,$%
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M0QI)I>@@(GYBO!\8WM<;APL[&A^OIATI+US#R<'3A>:E>8K^Y. _4$L#!!0
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M#T$UR7($7R)3&-,< PK+]#C,*%$^'P&WA H,.]RSEX/UN #64X+FYG:S:$V
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M<#8%J[,SM)N6$;L(A_K&W$A3"&!3G"9S9Q1_FJ0P>]CZB8XL^:&$:H$ WI@
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MMCGVE*SDF].X0%J=4D"OE^+<2',@AH/GV2._^,H4'(#&J:!RC*+)/A2SUM'
MP&33SR>9^ T/@8:C&<F:F:Z>.S?3GI>D[5X"4#SC1A2?3F\/F'AN'OFDIYE=
M&V?@P/_T3(10@"XUL/HS#VT#Y!_US'[9K>F1JVB:G"^P0*;WQ+2=1'P.RDD1
M\@36H=YJJ!CO8$43XC%Q*8[,W#796D+\\WBZ *W1XB(\)&A-RS#QPX7/,F),
M3@Q ,6-T,1D!#IE'S&^>;'TB@\8!BHG8JG.\>NXF.'AZR<3YQQ9PY!AE3;,I
MYHQR13AA'TAMAWU%AB8T!^*QWC_.2UKR1#7LD#WQ; X>$P/.NW;RF+(NV%HZ
M_D[<G$DP+-]&)\G*COG9*1KE1=?EC3.L3%@7TZ2::-<*IA1UKBE36.9.<ZQC
MIJAP*I/+S-R"\6(3(/$DM4&+:O%7:MJZ\&"D)=TI3V?!RCG=)P000!^LC^(;
M)5BD=AG:W//0YK9X+U9Z++L;F3&>)Z(8V\!(#JU[XH-I,$!GR,&?*'8MI;[X
MU&CF\]E8+Q8!;@KJ-\N.2_)XK4]#>3K3JT9Q1)78A6&R6X*F[@WCZ)/QA?*K
MQG.?D/>"RE-=@DTF82\-AJ)^#>1/%Z=I>R^8IV%Z/<3#7^..3W A^2/S]:69
M11KF/V/)0*$QQ-C#P?X10'I[!=6_),:(6^-56-"/LTMQQNN@.X94L8?3S+;-
MVD38QP"#S*E)M&- FQ!38D,-=)9T'HB"I2:3$&HQB476>FN2RM=B5,PI4=3'
MT"@SMJ."2XHSB=4(E ',B(\,R:8L,=;L9NZ="CWS\H$<W-CEY!:3$.J".TK:
MTPHPE0BUY7/C H[[,A7G:D,S8Z' IVE$W=G=9]=GKREFHP6A'>S"*'0>\4=X
M/8T6B8,(?DY5GXP]NKZMV<-#C@J 2:$N9=RHQ/AM6A1XPR(?M-^V]2/E!_KT
M/H88ODPPI#2.9GG<Q+?>O&XT3ZFAP(>,5>&++,S@SP!/BXYL%'G<,*40X2 7
M]SO&5_NBV***G2T&EM8?RIJ>S4!,#3[SM>F3QG,RDXN V%7US![G53]X;6 C
MZUP.M<'O,/M^'ETW+]:Y!_!BM-64_U 0V6)M>#QB@XFHK%7 8V^*MN968A6-
M^(XO+,%;6 U"V#C@MW>?&-@6_. O_6Y9]]4C8 ZWVFR^?,RQ%/*PI6C9ML8@
MO!72OY$6)]D?I\#A6%%R(D/"!'31.JOJM*OU#I$[@=DF?O9@NQ-5<Y8\\6=_
M:W:JC4;SSI]K5??.WQ;=ME-M'G>>X*YN>[V[+OZM\01SQ4K.^O&N3-:MMMS&
M4K?]B3C,<!GPL08W_.=7=??56&E0.>L)B!ESL]K>HG!,<[-AY"<#W#/)#U)+
MYV")\>U8!#]^X0%5#EP-!)CJ]^ SY@+_<E9\0)99I7 /7Q^^Q 7^'F(W3]C0
MN:N;LA_&QRLNN#&SWAJCWA>Y3.SYT+ELLNV37CQT4QQ=6XJC[WC5Z!Y18.9H
MP/UZ:[S$+O>N^S&6-E;L/#U/@,-W:N%8HJ(36+I]32(NXG0!5?!XQC/39"96
M9$S7JB^N78)Q'D"J)7AM9^[^.(Q38]O,/C],L\,C+?ITVH':BM6Z3JW9<IJ=
MNJF??)JUXT\KTJ#DYY*?U^-G]ZCI-!OM;>3GE>UQC_[;":M[YGDP<XI98S81
M32RU4UK+N$ZM>RTC]YSWJ*^VAW,5QA;)T)'C-E8U"/-9]4G5_I[N3LUI'1]O
M;G?6=2IV08EAA7-(^=6'^ 2/@<V?Y1Z+!&/.KFVY8#1:3JV]JF#,9\[G0*O[
MMCMUIU.O;6YW7C+V^J;P52^F;T")MW;/HCMNN^ET.JM*1PFYGFV#ZIUCIUYO
M[1[JL@ZMS97O8#3W"JN^!RJ 5>@?*:";C!XA8+N8((\05=W6!RR!*I;FF:T7
M6[?6<5QW5;%=0W2>,;Q9[OL2^]YIP+XWMW3?29?_1%FH>TNM[^L9]]R%5$#A
M:JVV5B754:O:.CIZ_-*<5K7>7K=6:&$=T=$3U!'A9)>N)INC';)]#!6VVRI'
M;G;D7%3FCE7MIHL(UJCU*IQE5SWV6W[X:\FRKYU;_$395U[+K =8;DX'.41L
M/^%9J27JPG:/ BO5A;DOI3!L^[3)/H]\:.U<9VN$;KG"K6_T.J[/,&Z@V<7D
M.V*6<&]W95L*;LTZ-65;M&%+5A@^3L76[M.JM45,7(Y\!%%_H<6BEZ:[M>G1
M6A:"/N#NV\?1^SSRD=*=)M#7V5+A_3K9HGYNO=F#TU!;L]KE"SGG+6T[0[7U
MFG/</-KYO&?)9-O,9&WGN+YU/+9])F.?1]YC+K=OPN7([1_YY!X5J:/&MIH2
M4Y5FL=F=KM7R>>EU3N%LCQ%:"^F\C%-6>[?7ZP".#6[U]FG.?1ZYKN>^VW$X
MFVC&!OCVG9WK1^26)LA#:I1WX.[;Q]O[//*1SDUM=T1N[OO*E[5]+S%*,F]I
MVPE:7*?A=G;^]%3)8]O-8[7VFM78)?S=CY%[D;BZS#O?T\LJ\Y<AK!4EV;WS
M5&W7<9NK=NC8OJS/"]V=X[ISW&QLV^YLGZ;:YY%[X<Q<F;=X.'GC<GK=B3^4
M^,[WF!I5/R2LO4,JH=EV&K4UCU-MD7/P4G?'=5KUK6M\L7U*:Y]'/GE4>1=R
MD6HFR/P0P/TB4E5NH^8<'[OKH;WMR$L^/&2^-YOMMIQ&:\TN%F5F<M]'[GD]
MRR>EM7U%7GXJ=N_+6@Y<M^;4ZJW#72AT*&M:'K+1M2/GJ-[9B8W>/MVYSR/+
MXMIR9,E4Y<CM'UDR53ER\V[36@[WUF91/F); J$3?.^J&M[S4H"]B<34G./.
M#@5BRJC;@UZGL'I?\C+H5H[<GTS[;_8=\ \S$+N7N75?0,7M2]T:I]Y:M0BJ
MS*GOU<C26RQ'EDQ5CMS^D<]4_7-\/[R$6SVS(?\B$A8HO?QIM(?[GEN#JU?N
MYK/3[_X\Z.#;'MSE,Y0O(Z!2,O*+8^1VQZFW5TBUE]&B<F2)'LN1)5.5(W=D
MY&,4DU9;#VITLSE?I/!6D0KK<BT]<Q)8!FDB_(=4V"TBR4N!>*LN>TM!GEL]
M>E@UY3WL_]R%LW=-9]46'24[[R@[MQY6!?Y\[+Q]UG"?1Y;PLARY>7@YOX'%
M]D'(/^B#\"L<IL+[@H7IL MH4O5@G<.A"@VNU"S5PF<RQ&^CE Z]AK/H\\WK
M=MUU3^_'H#D-7U:ODU;;.6[7G7ISS1.P93>:)]^A8Z?9ZCCNNM62)8K8CY$E
MBBA'/@U3S;RI>_'[N,O?YOV64=GJ]J-FM0WJ/U):XCGJDU@$U$]I_)9Q4/W%
MZ^P[RFOC2W@7?$6 *C.7W#F-XK^#_+VV$8"H2C<6_+K">XF(3WAPRT=Z\O%#
M&69FJ>-6FTV8^UTSG7DE(_PLAWW&@^3G5W((3_M/C5?_C/K >;$W\]4$F1J=
MZ/LZ;VFOU\',O9I#_FF[]VJ9/9NWHH4DSC?AX2#A_E<8'_^-WF"=<"^9ZAF^
MF;E\#&^$3E3,[*2>;3JS^ FG\UG%?1ZR*Q[V5.P[[%_2$^PK. C2A[UT6#[=
M2Q+!8D^#S4SXK"^59E_!/1ER3Z3$Z)N>TY"(6-6&B&]>'S5/.4ZS"L[5&BKR
MN5CQL_ EWSP?NG68RP4'WS1D7U3 0X==B5 "S[V7L?" ^1R89!RIF"<"_AH.
MTQ!V?</,2+/>,F:D.0FB9#5$2M[#BMMF=7_J*G\$_QLDP^#=_P-02P$"% ,4
M    "  "-)U<_:1Q+U40    ?@  $0              @ $     86=I;RTR
M,#(V,#0R.2YH=&U02P$"% ,4    "  "-)U<4GO,^6\"   L!P  $0
M        @ &$$   86=I;RTR,#(V,#0R.2YX<V102P$"% ,4    "  "-)U<
M(4,V/"L)  !]5   %0              @ $B$P  86=I;RTR,#(V,#0R.5]L
M86(N>&UL4$L! A0#%     @  C2=7!E$3+'H!0  %3$  !4
M ( !@!P  &%G:6\M,C R-C T,CE?<')E+GAM;%!+ 0(4 Q0    (  (TG5Q#
MT$*XTAT  % B 0 >              "  9LB  !A9VEO+30R.3(V>&9Y>&5X
D.3DQ96%R;FEN9RYH=&U02P4&      4 !0!0 0  J4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>agio-20260429_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agio-20260429.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2026-04-29</startDate>
            <endDate>2026-04-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001439222</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-04-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Agios Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36014</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">88 Sidney Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">649-8600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
